Gender‐specific association between preproendothelin‐1 genotype and reduction of systolic blood pressure during antihypertensive treatment‐‐‐results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)

Background: Studies suggest that endothelin‐1 contributes to the pathogenesis of hypertension. A G5665T gene polymorphism of preproendothelin‐1 has been shown to be associated with higher blood pressure in overweight patients. No study has yet determined the effect of this polymorphism on the change in blood pressure during antihypertensive treatment.

[1]  H. Melhus,et al.  The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial , 2002, Journal of hypertension.

[2]  A. Vasku,et al.  Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[3]  B. Lévy,et al.  Preproendothelin-1 Gene Polymorphism Is Related to a Change in Vascular Reactivity in the Human Mammary Artery In Vitro , 2002, Hypertension.

[4]  Y. Liu,et al.  Selected contribution: Gender differences in the endothelin-B receptor contribution to basal cutaneous vascular tone in humans. , 2001, Journal of applied physiology.

[5]  L. Beilin,et al.  Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy , 2001, Journal of hypertension.

[6]  H. Melhus,et al.  Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients , 2001, Journal of hypertension.

[7]  Z. Fortes,et al.  Ovarian Hormones Modulate Endothelin-1 Vascular Reactivity and mRNA Expression in DOCA-Salt Hypertensive Rats , 2001, Hypertension.

[8]  C. Held,et al.  Regression of left ventricular hypertrophy in human hypertension with irbesartan , 2001, Journal of hypertension.

[9]  K. Polderman,et al.  Modulation of plasma endothelin levels by the menstrual cycle. , 2000, Metabolism: clinical and experimental.

[10]  A. Marette,et al.  Gender differences in hemodynamic responses to endothelin-1. , 2000, Journal of cardiovascular pharmacology.

[11]  S. Vanni,et al.  Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. , 1999, Circulation research.

[12]  D. Arveiler,et al.  The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. , 1999, Hypertension.

[13]  A. Ergul,et al.  Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. , 1998, The Journal of pharmacology and experimental therapeutics.

[14]  H. Krum,et al.  The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. , 1998, The New England journal of medicine.

[15]  V. Miller,et al.  The Effect of Estrogen Replacement Therapy on Plasma Nitric Oxide and Endothelin-1 Levels in Postmenopausal Women , 1998, Annals of Internal Medicine.

[16]  K. Chatterjee,et al.  Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. , 1997, Circulation.

[17]  V. Miller,et al.  Gender and transcriptional regulation of NO synthase and ET-1 in porcine aortic endothelial cells. , 1997, American journal of physiology. Heart and circulatory physiology.

[18]  E. Schiffrin,et al.  Enhanced expression of endothelin‐1 gene in resistance arteries in severe human essential hypertension , 1997, Journal of hypertension.

[19]  K. Lamping,et al.  Effects of 17 beta-estradiol on coronary microvascular responses to endothelin-1. , 1996, The American journal of physiology.

[20]  M. J. Ashby,et al.  Expression of endothelin peptides and mRNA in the human heart. , 1996, Clinical science.

[21]  J. Puolakka,et al.  Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. , 1995, The Journal of clinical endocrinology and metabolism.

[22]  M. Polokoff,et al.  Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. , 1994, Pharmacological reviews.

[23]  S. Sasayama,et al.  Endothelin-1-selective receptor in the arterial intima of patients with hypertension. , 1994, Hypertension.

[24]  K. Polderman,et al.  Influence of Sex Hormones on Plasma Endothelin Levels , 1993, Annals of Internal Medicine.

[25]  A. Davenport,et al.  Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. , 1992, Circulation research.

[26]  A Sajantila,et al.  Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. , 1993, American journal of human genetics.

[27]  M. Shichiri,et al.  Plasma endothelin levels in hypertension and chronic renal failure. , 1990, Hypertension.

[28]  M. Yanagisawa,et al.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Kurihara,et al.  A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.